Experienced in Migraine

Dr. John D. Hudson

Sleep Medicine | Neurology
5508 Parkcrest Dr, Suite 310, 
Austin, TX 
Accepting New Patients
Experienced in Migraine
5508 Parkcrest Dr, Suite 310, 
Austin, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Hudson is a Sleep Medicine specialist and a Neurologist in Austin, Texas. Dr. Hudson is rated as an Experienced provider by MediFind in the treatment of Migraine. His top areas of expertise are Restless Legs Syndrome, Obstructive Sleep Apnea, Excessive Daytime Sleepiness, and Drowsiness. Dr. Hudson is currently accepting new patients.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 6 clinical trials in the study of Migraine.

Specialties
Sleep Medicine
Neurology
Licenses
Psychiatry & Neurology in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Sendero
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

5508 Parkcrest Dr, Suite 310, Austin, TX 78731

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: SUVN-G3031
Study Phase: Phase 2
A Multi-Center, Randomized, Double-Blind, Sham-Controlled Study to Evaluate the NTX100 Neuromodulation System for Patients With Medication-Refractory Primary Restless Legs Syndrome (RLS) - The RESTFUL Study
A Multi-Center, Randomized, Double-Blind, Sham-Controlled Study to Evaluate the NTX100 Neuromodulation System for Patients With Medication-Refractory Primary Restless Legs Syndrome (RLS) - The RESTFUL Study
Enrollment Status: Completed
Publish Date: October 08, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polysulfate Sodium Compared With Placebo in Participants With Knee Osteoarthritis Pain
A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polysulfate Sodium Compared With Placebo in Participants With Knee Osteoarthritis Pain
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2024
Intervention Type: Drug
Study Drug: Pentosan Polysulfate Sodium
Study Phase: Phase 2/Phase 3
ImThera Medical Targeted Hypoglossal Neurostimulation Study #3
ImThera Medical Targeted Hypoglossal Neurostimulation Study #3
Enrollment Status: Completed
Publish Date: February 07, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Terminated
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea
Enrollment Status: Completed
Publish Date: December 12, 2022
Intervention Type: Drug
Study Drugs: AD109, AD504, Atomoxetine Hydrochloride
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
Enrollment Status: Completed
Publish Date: November 12, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: August 19, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
Enrollment Status: Completed
Publish Date: January 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 17 Less Clinical Trials

11 Total Publications

RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates.
RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates.
Journal: Sleep medicine: X
Published: May 23, 2024
Similar Doctors
Distinguished in Migraine
Dr. Hector F. Colon
Neurology | Nephrology
Distinguished in Migraine
Dr. Hector F. Colon
Neurology | Nephrology
2207 Clear Creek Rd, Suite 205, 
Killeen, TX 
 (53.7 miles away)
254-526-2343
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hector Colon is a Neurologist and a Nephrologist in Killeen, Texas. Dr. Colon is rated as a Distinguished provider by MediFind in the treatment of Migraine. His top areas of expertise are Migraine, Migraine with Brainstem Aura, Restless Legs Syndrome, and Benign Rolandic Epilepsy. Dr. Colon is currently accepting new patients.

Distinguished in Migraine
Dr. Anwarul U. Haq
Neurology | Nephrology
Distinguished in Migraine
Dr. Anwarul U. Haq
Neurology | Nephrology

Scott And White Clinic

1605 S 31st St, Baylor Scott And White Cente, 
Temple, TX 
 (56.8 miles away)
254-215-0100
Languages Spoken:
English, French, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Anwarul Haq is a Neurologist and a Nephrologist in Temple, Texas. Dr. Haq is rated as an Advanced provider by MediFind in the treatment of Migraine. His top areas of expertise are Migraine, Headache, Migraine with Brainstem Aura, and Chronic Inflammatory Demyelinating Polyneuropathy. Dr. Haq is currently accepting new patients.

Distinguished in Migraine
Dr. Bill D. Davis
Neurology
Distinguished in Migraine
Dr. Bill D. Davis
Neurology

Advent Health - San Marcos

1305 Wonder World Drive, Suite 307, 
San Marcos, TX 
 (35.3 miles away)
512-353-8658
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bill Davis is a Neurologist in San Marcos, Texas. Dr. Davis is rated as a Distinguished provider by MediFind in the treatment of Migraine. His top areas of expertise are Cerebellar Degeneration, Peripheral Neuropathy, Migraine, and Progressive Myoclonic Epilepsy. Dr. Davis is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hudson's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile